HCW Biologics Inc.HCWBEarnings & Financial Report
HCW Biologics Inc. is a clinical-stage biotechnology company focused on researching and developing novel immunotherapies and biological products targeting unmet medical needs in oncology, chronic inflammatory disorders, and autoimmune diseases. It primarily operates in the U.S., advancing multiple pipeline candidates through early to mid-stage clinical trials.
HCWB Q4 FY2024 Key Financial Metrics
Revenue
$394.8K
Gross Profit
$79.0K
Operating Profit
$-3.1M
Net Profit
$-3.4M
Gross Margin
20.0%
Operating Margin
-795.9%
Net Margin
-854.4%
YoY Growth
-70.2%
EPS
$-10.47
HCW Biologics Inc. Q4 FY2024 Financial Summary
HCW Biologics Inc. reported revenue of $394.8K (down 70.2% YoY) for Q4 FY2024, with a net profit of $-3.4M (up 68.4% YoY) (-854.4% margin). Cost of goods sold was $315.8K, operating expenses totaled $3.2M.
Key Financial Metrics
| Total Revenue | $394.8K |
|---|---|
| Net Profit | $-3.4M |
| Gross Margin | 20.0% |
| Operating Margin | -795.9% |
| Report Period | Q4 FY2024 |
HCW Biologics Inc. Annual Revenue by Year
HCW Biologics Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $2.6M).
HCW Biologics Inc. Quarterly Revenue & Net Profit History
HCW Biologics Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $394.8K | -70.2% | $-3.4M | -854.4% |
| Q3 FY2024 | $426.4K | -50.0% | $-3.9M | -915.1% |
| Q2 FY2024 | $618.9K | -0.6% | $-15.3M | -2469.1% |
| Q1 FY2024 | $1.1M | +2590.1% | $-7.5M | -662.8% |
| Q4 FY2023 | $1.3M | -1.3% | $-10.7M | -806.7% |
| Q3 FY2023 | $853.1K | -52.8% | $-4.9M | -578.9% |
| Q2 FY2023 | $622.8K | +37.2% | $-4.3M | -691.1% |
| Q4 FY2022 | $1.3M | — | $-5.4M | -403.9% |
Income Statement
| Q4 2022 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $622807 | $853102 | $1.3M | $1.1M | $618854 | $426423 | $394803 |
| YoY Growth | N/A | 37.2% | -52.8% | -1.3% | 2590.1% | -0.6% | -50.0% | -70.2% |
Balance Sheet
| Q4 2022 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $46.8M | $39.5M | $35.6M | $28.5M | $30.4M | $26.8M | $26.6M | $30.2M |
| Liabilities | $9.4M | $10.9M | $11.7M | $15.1M | $21.7M | $33.1M | $36.5M | $37.0M |
| Equity | $37.4M | $28.6M | $23.9M | $13.5M | $8.7M | $-6.3M | $-10.0M | $-6.8M |
Cash Flow
| Q4 2022 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.8M | $-9.4M | $-5.6M | $-3.9M | $-3.6M | $-4.9M | $-2.9M | $-2.8M |